Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

Inclusion Criteria:

Patients must have a histologically confirmed diagnosis of non- muscle invasive urothelial carcinoma of the bladder at the study institution prior to the beginning of the study. This includes patients with:

* High grade Ta papillary lesion(s)
* High or low grade T1 papillary lesion(s)
* Carcinoma In Situ (CIS), with or without Ta or T1 papillary tumor(s) of any grade The patient must have Bacillus Calmette-Guerin (BCG) refractory or recurrent non-muscle invasive bladder cancer
* Refractory disease is defined as evidence of persistent high risk bladder cancer (high grade Ta, T1 and/or CIS) at the first cystoscopic exam after the initial 6 week induction course of BCG or at the 6 month cystoscopic exam.
* Recurrent disease is defined as reappearance of disease after achieving a tumor- free status by 6 months following a full induction course of BCG with or without maintenance BCG. Participants must have recurred within 18 months following the last dose of BCG.

  * Low-grade superficial (Ta) disease will not be considered recurrent.
  * Patients must exhibit disease recurrence after receiving some form of standard intravesical therapy that must include a minimum of one induction course of BCG and may also include prior exposure to mitomycin, interferon, single agent gemcitabine or taxane therapy or maintenance.
* Patients must be eligible for radical cystectomy and refuse this standard of care treatment or not be a surgical candidate for radical cystectomy based on other comorbidities.
* All grossly visible disease in the bladder must be fully resected and pathologic stage will be confirmed at the study institution.
* Patients enrolled in other clinical trials must have received their last treatment at least 6 weeks prior to enrollment.
* Age \> 18 and must be able to read, understand and sign informed consent
* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance Status: ECOG of 0 or 1 including patients who are not surgical candidates due to comorbid conditions.
* Women of childbearing potential must have a negative pregnancy test.
* All patients of childbearing potential must be willing to consent to using effective contraception, i.e., intrauterine device (IUD), Birth control pills, Depo-Provera, and condoms while on treatment and for 3 months after their participation in the study ends.
* No experimental intravesical therapy within 6 weeks of study entry

Exclusion Criteria:

* History of severe hypersensitivity reaction (≥grade 3) to docetaxel
* History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs
* Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are already on I these treatments)
* Concurrent malignancy diagnosed within 6 months of entry to the study.
* Concurrent treatment with any systemic chemotherapeutic agent.
* Inadequate organ and bone marrow function as evidenced by:

  * Hemoglobin: less than 8.0 g/dL
  * Absolute neutrophil count: less than 1.5 x 10\^9/L
  * Platelet count: less than 80x 10\^9/L
  * Aspartate Aminotransferase Test (AST) / Serum Glutamic Oxaloacetic Transaminase (SGOT) and/or ( Alanine Aminotransferase Test (ALT)/ Serum Glutamic Pyruvic Transaminase (SGPT) \>2.5 x upper limit of normal (ULN);
  * Total bilirubin \>1.5 x ULN
  * Serum creatinine \>2 x ULN. If creatinine 1.5 - 2.0 x ULN, creatinine clearance will be calculated according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula and patients with creatinine clearance \<30 mL/min should be excluded.
* Women who are pregnant or lactating.
* Documented history of vesicoureteral reflux or an indwelling urinary stent.
* Participation in any other research protocol involving administration of an investigational agent within 6 weeks prior to study entry.
* No Institutional Review Board (IRB) approved signed consent form